Oppenheimer & Co.

Oppenheimer & Co. is out with a research report on Capella Education Co. (NASDAQ: CPLA) and it has an Outperform rating and a $47 price target on shares. In a note to clients, Oppenheimer & Co. writes, "3Q11 EPS of $0.66 (-18% y/y) exceeded our estimate/consensus of $0.58/$0.60 via revenue...

Oppenheimer & Co. is out with a research report on Halozyme Therapeutics, Inc. (NASDAQ: HALO) and it has an Outperform rating and a $18 price target on shares. In a note to clients, Oppenheimer writes, " On 10/21, HALO released results from two n=110 patient Phase II studies comparing HALO's...

Oppenheimer & Co. is out with a research report on CarMax (NYSE: KMX) and it has an Outperform rating and a $38 price target on shares. In a note to clients, Oppenheimer & Co. writes, "CarMax represents one of the most compelling intermediate- and longer term unit expansion stories in the...

Oppenheimer & Co. is out with a research report on KLA-Tencor (NASDAQ: KLAC) and it has an Outperform rating and a $50 price target on shares. In a note to clients, Oppenheimer & Co. writes, "Foundries are coming back along with memory and logic in CQ4-11. TSMC is back in CQ4 in KLAC's...

Oppenheimer & Co. is out with a research report on ServiceSource (NASDAQ: SREV) and it has an Outperform rating and a $22 price target on shares. In a note to clients, Oppenheimer & Co. writes, "Despite the macro volatility and a sizable customer not renewing its contract, SREV pre-...

Oppenheimer & Co. is out with a research report on TPC Group (NASDAQ: TPCG) and it has an Outperform rating and a $33 price target on shares. In a note to clients, Oppenheimer & Co. writes, "In conjunction with our meetings, TPCG in an 8-K introduced "future" EBITDA guidance up 2-3x from...

Oppenheimer & Co. is out with a research report on Jarden Corporation (NYSE: JAH) and it has an Outperform rating and a $43 price target on shares. In a note to clients, Oppenheimer writes, "Our recent meeting with JAH management was encouraging and gave us increased confidence in our...

Oppenheimer & Co. is out with a research report on Teradata Corp. (NYSE: TDC) and it has an Outperform rating and a $61 price target on shares. In a note to clients, Oppenheimer & Co. writes, "Despite the economic uncertainty, the malaise in Europe and little commentary from management on...

Oppenheimer & Co. is out with a research report on Resources Connection Inc. (NASDAQ: RECN) and it has a Perform rating on shares. In a note to clients, Oppenheimer & Co. writes, "F1Q12 EPS of $0.06 (+34% y/y) was in line with our estimate and topped consensus of $0.05. Notably, the 62%...

Oppenheimer & Co. is out with a research report on Church & Dwight (NYSE: CHD) and it has an Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "We believe commodity and pricing environment are improving for CHD, and are highlighting the name as well...

Oppenheimer & Co. is out with a research report on Visa (NYSE: V) and it has an Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "We are highly attracted to Visa's powerful brand, its vast global acceptance network and its strong business model. We believe the...

Oppenheimer & Co. is out with a research report on Mindray (NYSE: MR) and it has an Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "We view MR as a dominant key player in China's medical device industry. We think MR will grow on the back of US recovery,...

Oppenheimer & Co. is out with a research report on New Oriental Education (NYSE: EDU) and it has an Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "We are confident in EDU's leading market position and continue to be attracted to its growth strategy in China's...

Oppenheimer & Co. is out with a research report on Biogen Idec Inc. (NASDAQ: BIIB) and it has an Outperform rating and a $109 price target on shares. In a note to clients, Oppenheimer & Co. writes, "With focus on upcoming ph.III CONFIRM results for BG-12 in MS, we performed an in-depth...

Oppenheimer & Co. is out with a research report on ONEOK Partners (NYSE: ONK) and it has an Outperform rating and a $54 price target on shares. In a note to clients, Oppenheimer & Co. writes, "We went into OKS's 2011 Analyst Day with high expectations, and OKS came through with positive...